Endo International plc Stock, NASDAQ:ENDP
MINERVA HOUSE, SIMMONSCOURT ROAD, BALLSBRIDGE, DUBLIN 4, IRELAND 00000
Number of Employees: 2910
Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's U.S. Branded Pharmaceuticals segment offers pain management products, such as Lidoderm, OPAN ER, Percocet, and Voltare Gel. This segment also provides Supprelin LA for central precocious puberty treatment; XIAFLEX for treating Peyronie's and Dupuytren's contracture diseases; Fortesta Gel for hypogonadism treatment; Testim Gel for the treatment of endogenous testosterone; Frova for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; Vantas for the palliative treatment of prostate cancer; Aveed for the treatment of low testosterone; TESTOPEL, a long-acting implantable pellet; and NASCOBAL, a nasal spray. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, women's health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.